Abstract 482P
Background
Identification of EGFRm in early-stage NSCLC determines the prognosis and is predictive of response to targeted therapy. EARLY-EGFR (NCT04742192) is the first real-world study describing the prevalence of EGFRm and treatment patterns in pts with early-stage NSCLC.
Methods
This prospective, non-interventional study consecutively enrolled pts with surgically-resected stage IA-IIIB non-squamous NSCLC from 14 countries across Asia, Latin America and the Middle East and Africa. [EJ1] [NP[2] Here, we describe the prevalence of EGFRm and its subtypes, clinico-demographics and treatment patterns for patients enrolled from Aug 2021 to Sep 2022 in the Singapore cohort.
Results
A total of 71 pts were enrolled (mean±SD age 67.3±8.5 yrs); 54.9% were females and 66.2% were never smokers. Most pts had adenocarcinoma (98.6%), stage I NSCLC (73.2%), right lung tumour (64.8%), T2a/b stage (52.1%) and pN0 (81.7%). About 83% (38/46) of the cases were discussed in a multidisciplinary team (MDT) meeting (pre-operative: 55.3%, post-operative: 31.6%, both: 13.2%). The EGFRm prevalence was 63.8% (44/69). The EGFR subtypes included exon-19 del (29, 65.9%), exon 21-L858R (11, 25.0%) and uncommon mutations (4, 9.1%). Of 15 pts with PD-L1 test report, 8 had PD-L1>1%; 5 of them had EGFRm. Overall, 76.1% (54/71) underwent only surgical resection without any adjuvant treatment. Adjuvant therapy was planned in 16 pts (22.5%): IA (1), IB (04), IIA (2), IIB (5), IIIA (3), IIIB (1). Of the 48 pts with stage IB-IIIB, 15 (31.3%) were prescribed systemic therapy (ST); targeted therapy was planned in 2 pts. No pt received neo-adjuvant ST. Table: 482P
Prevalence of EGFRm
Characteristics | N=71, n (%) | Mutation rate | |||
EGFRm (N=44), n | EGFR wild type (N=25), n | Mutation rate (%) | |||
Age (yrs) | <60 | 14 (19.7) | 10 | 3 | 76.9 |
60-80 | 54 (76.1) | 31 | 22 | 58.5 | |
>80 | 3 (4.2) | 3 | 0 | 100 | |
Gender | Female | 39 (54.9) | 25 | 13 | 65.8 |
Male | 32 (45.1) | 19 | 12 | 61.3 | |
Histology | Adenocarcinoma | 70 (98.6) | 43 | 25 | 63.2 |
Others | 01 (1.4) | 1 | 0 | 100 | |
Smoking* | Current | 04 (5.6) | 2 | 1 | 66.7 |
Former | 20 (28.2) | 9 | 11 | 45.0 | |
Never | 47 (66.2) | 33 | 13 | 71.7 | |
Stage (AJCC 8th edi.) | IA | 23 (32.4) | 15 | 8 | 65.2 |
IB | 29 (40.8) | 17 | 12 | 58.6 | |
IIA | 3 (4.2) | 1 | 1 | 50.0 | |
IIB | 09 (12.7) | 5 | 3 | 62.5 | |
IIIA | 06 (8.4) | 5 | 1 | 83.3 | |
IIIB | 01 (1.4) | 1 | 0 | 100.0 |
Two pts failed EGFR test *p = 0.051: comparison between current and former vs. never smoker Unknown/missing data not included
Conclusions
Our study reports a high prevalence of EGFRm (63.8%). Of 29 and 19 pts with stage IB and II-III NSCLC, ST was planned in 4 and 9 pts, respectively, highlighting the need to comply with international guidelines. Our data calls for biomarker profiling of early-stage NSCLC to ensure appropriate management through MDT.
Clinical trial identification
NCT04742192.
Editorial acknowledgement
Medical writing support was provided by Prajakta Nachane (M. Pharm) of Fortrea Scientific Pvt Ltd funded by AstraZeneca FZ LLC in accordance with GPP 2022 guidelines.
Legal entity responsible for the study
AstraZeneca International.
Funding
AstraZeneca International.
Disclosure
P.L. Chia: Other, Personal, Advisory Board: AstraZeneca, Merck, Amgen, Pfizer, Bayer; Financial Interests, Personal, Other, Honoraria for symposium: AstraZeneca, Lung Cancer Consortium Singapore; Financial Interests, Institutional, Research Funding: AstraZeneca. J.T. Kit Chung: Financial Interests, Personal, Speaker, Consultant, Advisor, Advisory and Consultancy with AstraZeneca, BMS, MSD: AstraZeneca, BMS, MSD. A. Asmat: Financial Interests, Personal, Other, Honorarium from MSD for participation in an early stage NSCLC Expert Input Forum in August 2023: MSD. R. Huggenberger: Financial Interests, Personal, Full or part-time Employment, I am an employee of AstraZeneca: AstraZeneca; Financial Interests, Personal, Stocks/Shares: AstraZeneca, Innate Pharma, Chinook Therapeutics, Adaptimmune Therapeutics, CStone Pharmaceuticals, Allogene Therapeutics, Imugene Limited, Swedish Orphan Biovitrium, Cullinan Oncology, Blueprint Medicines, GSK, Gritstone Bio, Compugen, Arcutis Biotherapeutics, Syndax Pharmaceuticals, Eli Lilly. A. Verma: Other, Personal, Full or part-time Employment: AstraZeneca. R.A. Soo: Financial Interests, Personal, Advisory Board: Amgen, AstraZeneca, Bayer, BMS, Lily, Merck, Novartis, Pfizer, Roche, Taiho, Takeda, Yuhan, Thermo Fisher, Janssen, Merck Serono, Puma Biotech; Financial Interests, Personal, Invited Speaker: Boehringer Ingelheim; Financial Interests, Institutional, Research Grant: AstraZeneca, Boehringer Ingelheim.
Resources from the same session
540P - Phase III study of serplulimab plus chemotherapy as first-line therapy for advanced squamous non-small cell lung cancer: ASTRUM-004 Asian subgroup
Presenter: Caicun Zhou
Session: Poster Display
Resources:
Abstract
541P - Integrated analysis of randomized controlled trials IMpower130 and IMpower132 for advanced non-squamous non-small cell lung cancer (NSCLC)
Presenter: Hibiki Udagawa
Session: Poster Display
Resources:
Abstract
542P - First-line HLX07 plus serplulimab with or without chemotherapy versus serplulimab plus chemotherapy in advanced/recurrent squamous non-small cell lung cancer: A phase II study
Presenter: Zhen Wang
Session: Poster Display
Resources:
Abstract
543P - A multicenter retrospective study to investigate risk factors for immune checkpoint inhibitor-induced pneumonitis in non-small cell lung cancer patients with comorbid interstitial pneumonia
Presenter: Yuriko Ishida
Session: Poster Display
Resources:
Abstract
544P - Single cell level investigation of blood cells representing immune checkpoint inhibitor response in lung adenocarcinoma patients
Presenter: Juyong Seong
Session: Poster Display
Resources:
Abstract
545P - Completion of pembrolizumab in advanced non-small cell lung cancer: Real-world outcomes after two years of therapy (COPILOT)
Presenter: Andrew Fantoni
Session: Poster Display
Resources:
Abstract
546P - Combination therapy with anti-PD-1 antibody plus angiokinase inhibitor exerts synergistic antitumor effect against malignant mesothelioma via tumor microenvironment modulation
Presenter: Akio Tada
Session: Poster Display
Resources:
Abstract
547P - Immunotherapy outcome in advanced/metastatic lung cancer patients in real-world experience: Indian data
Presenter: Naveen K
Session: Poster Display
Resources:
Abstract
548P - B-Myb acts as a mentor instant promoter in non-small cell lung cancer by modifying the PD-1/PD-L1 axis
Presenter: Pan Xu
Session: Poster Display
Resources:
Abstract
549P - Drug-induced interstitial lung disease in patients with non-small cell lung cancer treated with immunotherapy for postoperative recurrence: Evaluation of CT findings and histopathological findings of the background lung
Presenter: shodai fujimoto
Session: Poster Display
Resources:
Abstract